weight loss drug news today glp-1 october 2025 Agonists Market Report 2025-2033, By Product, Molecule, and Geo GLP-1 Weight-Loss Drug Demonstration Begins

Because of this, the Diabetes Prevention Program study has shown that for people with prediabetes or metabolic risk , metformin can gently support weight management and delay diabetes development over the long term

They affect 20%30% of patients and usually cease during long-term therapy after a few weeks

These effects were mostly accompanied by decreased maternal food consumption and a reduction in maternal weight

Shortly after the drug was released, it was aggressively marketed by Novo Nordisk and quickly became popular for its ability to help with weight loss, which was considered an off-label use

only provided d-allulose but was not involved in the conduction of current study including planning and performing the experiments, making figures, statistical analysis, manuscript preparation and review

The 'Switch' is On: Proving the Viability of Oral Maintenance Therapy The ATTAIN-MAINTAIN study was a first-of-its-kind Phase 3 trial designed to answer a critical clinical question: can patients who have successfully lost weight on injectable GLP-1s (Wegovy or Zepbound) switch directly to an oral agent and maintain their results